Details for: BRENZYS
Company: SAMSUNG BIOEPIS CO., LTD
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02455323 | BRENZYS | ETANERCEPT | 50 MG / ML | SOLUTION | SUBCUTANEOUS |
| 02455331 | BRENZYS | ETANERCEPT | 50 MG / ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - ENBREL (etanercept) - Assessing the potential harm to the developing babies of mothers treated with ENBREL
Summary Safety Review - ENBREL (etanercept) - Schizophrenia like symptoms
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - ENBREL (etanercept) - Assessing the potential harm to the developing babies of mothers treated with ENBREL
Summary Safety Review - ENBREL (etanercept) - Schizophrenia like symptoms
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.